世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
ファーミング市場。世界の産業動向、シェア、サイズ、成長、機会、および2021-2026年の予測Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global pharmerging market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of... もっと見る
サマリーThe global pharmerging market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product outlook, indication and distribution channel. Breakup by Product Outlook: Pharmaceuticals Patented Prescription Drugs Generic Prescription Drugs OTC Drugs Healthcare Medical Devices Clinical Diagnosis Others Breakup by Indication: Lifestyle Diseases Cancer and Autoimmune Diseases Infectious Diseases Others Breakup by Distribution Channel: Hospitals Retail Pharmacies Online Stores Others Breakup by Country: Tier I China Tier II India Brazil Russia South Africa Tier II Argentina Mexico Poland Ukraine Turkey Saudi Arabia Egypt Algeria Nigeria Thailand Indonesia Pakistan Others Competitive Landscape: The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited. Key Questions Answered in This Report: How has the global pharmerging market performed so far and how will it perform in the coming years? What are the key regional markets? What is the impact of COVID-19 on global pharmerging market? What is the breakup of the market based on the product outlook? What is the breakup of the market based on the indication? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the market? What is the structure of the global pharmerging market and who are the key players? What is the degree of competition in the market? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Pharmerging Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product 6.1 Pharmaceutical 6.1.1 Market Trends 6.1.2 Major Types 6.1.2.1 Patented Prescription Drugs 6.1.2.2 Generic Prescription Drugs 6.1.2.3 OTC Drugs 6.1.3 Market Forecast 6.2 Healthcare 6.2.1 Market Trends 6.2.2 Major Types 6.2.2.1 Medical Devices 6.2.2.2 Clinical Diagnosis 6.2.2.3 Others 6.2.3 Market Forecast 7 Market Breakup by Indication 7.1 Lifestyle Diseases 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Cancer and Autoimmune Diseases 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Infectious Diseases 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Hospitals 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Retail Pharmacies 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Online Stores 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Country 9.1 Tier I 9.1.1 China 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.2 Tier II 9.2.1 India 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Brazil 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 Russia 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Africa 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.3 Tier III 9.3.1 Argentina 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 Mexico 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 Poland 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Ukraine 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Turkey 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Saudi Arabia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Egypt 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.3.8 Algeria 9.3.8.1 Market Trends 9.3.8.2 Market Forecast 9.3.9 Nigeria 9.3.9.1 Market Trends 9.3.9.2 Market Forecast 9.3.10 Thailand 9.3.10.1 Market Trends 9.3.10.2 Market Forecast 9.3.11 Indonesia 9.3.11.1 Market Trends 9.3.11.2 Market Forecast 9.3.12 Pakistan 9.3.12.1 Market Trends 9.3.12.2 Market Forecast 9.3.13 Others 9.3.13.1 Market Trends 9.3.13.2 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Sanofi S.A. 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Pfizer Inc. 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 AstraZeneca Plc. 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 Financials 13.3.3.4 SWOT Analysis 13.3.4 GlaxoSmithKline Plc. 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.3 SWOT Analysis 13.3.5 F. Hoffmann-La Roche AG (Roche AG) 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Eli Lilly and Company 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.6.4 SWOT Analysis 13.3.7 Johnson & Johnson 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Abbott Laboratories 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.8.4 SWOT Analysis 13.3.9 Novartis AG 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 Teva Pharmaceutical Limited 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financial 13.3.10.4 SWOT Analysis
SummaryThe global pharmerging market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product outlook, indication and distribution channel. Breakup by Product Outlook: Pharmaceuticals Patented Prescription Drugs Generic Prescription Drugs OTC Drugs Healthcare Medical Devices Clinical Diagnosis Others Breakup by Indication: Lifestyle Diseases Cancer and Autoimmune Diseases Infectious Diseases Others Breakup by Distribution Channel: Hospitals Retail Pharmacies Online Stores Others Breakup by Country: Tier I China Tier II India Brazil Russia South Africa Tier II Argentina Mexico Poland Ukraine Turkey Saudi Arabia Egypt Algeria Nigeria Thailand Indonesia Pakistan Others Competitive Landscape: The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited. Key Questions Answered in This Report: How has the global pharmerging market performed so far and how will it perform in the coming years? What are the key regional markets? What is the impact of COVID-19 on global pharmerging market? What is the breakup of the market based on the product outlook? What is the breakup of the market based on the indication? What is the breakup of the market based on the distribution channel? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the market? What is the structure of the global pharmerging market and who are the key players? What is the degree of competition in the market? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Pharmerging Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product 6.1 Pharmaceutical 6.1.1 Market Trends 6.1.2 Major Types 6.1.2.1 Patented Prescription Drugs 6.1.2.2 Generic Prescription Drugs 6.1.2.3 OTC Drugs 6.1.3 Market Forecast 6.2 Healthcare 6.2.1 Market Trends 6.2.2 Major Types 6.2.2.1 Medical Devices 6.2.2.2 Clinical Diagnosis 6.2.2.3 Others 6.2.3 Market Forecast 7 Market Breakup by Indication 7.1 Lifestyle Diseases 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Cancer and Autoimmune Diseases 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Infectious Diseases 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Distribution Channel 8.1 Hospitals 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Retail Pharmacies 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Online Stores 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Country 9.1 Tier I 9.1.1 China 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.2 Tier II 9.2.1 India 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Brazil 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 Russia 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Africa 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.3 Tier III 9.3.1 Argentina 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 Mexico 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 Poland 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Ukraine 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Turkey 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Saudi Arabia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Egypt 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.3.8 Algeria 9.3.8.1 Market Trends 9.3.8.2 Market Forecast 9.3.9 Nigeria 9.3.9.1 Market Trends 9.3.9.2 Market Forecast 9.3.10 Thailand 9.3.10.1 Market Trends 9.3.10.2 Market Forecast 9.3.11 Indonesia 9.3.11.1 Market Trends 9.3.11.2 Market Forecast 9.3.12 Pakistan 9.3.12.1 Market Trends 9.3.12.2 Market Forecast 9.3.13 Others 9.3.13.1 Market Trends 9.3.13.2 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 13.3 Profiles of Key Players 13.3.1 Sanofi S.A. 13.3.1.1 Company Overview 13.3.1.2 Product Portfolio 13.3.1.3 Financials 13.3.1.4 SWOT Analysis 13.3.2 Pfizer Inc. 13.3.2.1 Company Overview 13.3.2.2 Product Portfolio 13.3.2.3 Financials 13.3.2.4 SWOT Analysis 13.3.3 AstraZeneca Plc. 13.3.3.1 Company Overview 13.3.3.2 Product Portfolio 13.3.3.3 Financials 13.3.3.4 SWOT Analysis 13.3.4 GlaxoSmithKline Plc. 13.3.4.1 Company Overview 13.3.4.2 Product Portfolio 13.3.4.3 Financials 13.3.4.3 SWOT Analysis 13.3.5 F. Hoffmann-La Roche AG (Roche AG) 13.3.5.1 Company Overview 13.3.5.2 Product Portfolio 13.3.5.3 Financials 13.3.5.4 SWOT Analysis 13.3.6 Eli Lilly and Company 13.3.6.1 Company Overview 13.3.6.2 Product Portfolio 13.3.6.3 Financials 13.3.6.4 SWOT Analysis 13.3.7 Johnson & Johnson 13.3.7.1 Company Overview 13.3.7.2 Product Portfolio 13.3.7.3 Financials 13.3.7.4 SWOT Analysis 13.3.8 Abbott Laboratories 13.3.8.1 Company Overview 13.3.8.2 Product Portfolio 13.3.8.3 Financials 13.3.8.4 SWOT Analysis 13.3.9 Novartis AG 13.3.9.1 Company Overview 13.3.9.2 Product Portfolio 13.3.9.3 Financials 13.3.9.4 SWOT Analysis 13.3.10 Teva Pharmaceutical Limited 13.3.10.1 Company Overview 13.3.10.2 Product Portfolio 13.3.10.3 Financial 13.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
IMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/20 10:26 143.76 円 160.81 円 193.57 円 |
